25 results
424B5
IMPLQ
Impel Pharmaceuticals Inc
5 Oct 23
Prospectus supplement for primary offering
5:19pm
, corporate integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings
8-K
EX-10.1
IMPLQ
Impel Pharmaceuticals Inc
7 Sep 23
Entry into a Material Definitive Agreement
4:19pm
or oversight body of such Person or any committee thereof authorized to act on behalf of such board (or equivalent body).
“Borrower” has the meaning set … oversight with respect to any Product or any Product Commercialization and Development Activities relating to any Product, including the FDA and all
8-K
EX-10.1
IMPLQ
Impel Pharmaceuticals Inc
21 Aug 23
Entry into a Material Definitive Agreement
8:33am
of directors or equivalent management or oversight body of such Person or any committee thereof authorized to act on behalf of such board … regulatory or supervisory oversight with respect to any Product or
-28-
4882-5123-79004861-6868-3896 v.123
any Product Commercialization
PRE 14A
i79 ba3t0
14 Apr 23
Preliminary proxy
4:11pm
DEF 14A
6ikjgf
26 Apr 22
Definitive proxy
4:16pm
10-K
2hxwapwngveg509g1wya
29 Mar 22
Annual report
5:09pm
424B4
vu5hr5
10 Sep 21
Prospectus supplement with pricing info
4:01pm
DRS
9seuvefi
25 Aug 21
Draft registration statement
12:00am